Subjects n | 78 |
Age years | 32 (8–59) |
Sex | |
Female | 24 (31) |
Male | 54 (69) |
Weight kg | 54 (24–83) |
Region | |
Western Europe | 3 (4) |
Eastern Europe | 40 (51) |
Asia | 18 (23) |
Africa | 17 (22) |
Disease type | |
Pulmonary disease alone | 76 (97) |
Pulmonary and extrapulmonary disease | 2 (3) |
Cavitary disease | |
None or unknown | 42 (54) |
Yes | 36 (46) |
Resistance type | |
MDR-TB | 8 (10) |
Pre-XDR-TB | 26 (33) |
XDR-TB | 44 (56) |
History of prior TB treatment | |
No | 14 (18) |
Yes | 64 (82) |
Comorbidities | |
HIV co-infection | 12 (15) |
HCV co-infection | 11 (14) |
HBV co-infection | 3 (4) |
Diabetes mellitus | 6 (8) |
Baseline culture status | |
Negative | 13 (17) |
Positive | 65 (83) |
Culture status at 24 weeks# | |
Negative | 53 (80) |
Positive | 11 (17) |
Contaminated | 1 (2) |
Pending | 1 (2) |
Drugs used in optimised background regimens# | |
Linezolid | 60 (91) |
Clofazimine | 50 (76) |
Fluoroquinolones | 45 (68) |
Aminoglycosides or capreomycin | 45 (68) |
Carbapenems | 33 (50) |
Bedaquiline | 12 (18) |
Active drugs in regimens (excluding delamanid)# | |
Negative culture status at 24 weeks | 3.3 (0–5) |
Positive culture status at 24 weeks | 2.3 (0–5) |